To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib

NCT01548170 | Completed Phase 1

• 2 other identifiers: KS-ONCOFARMA-012010-023739-41
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

Sunitinib is an ATP competitive tyrosine kinase inhibitor of several membrane receptors including VEGFR-1, -2, and -3, PDGFR-α and -β, c-KIT, CSF-1R, FLT-3, and RET. Through this molecular mode of action, sunitinib is able to avoid tumoral angiogenesis and proliferation. Sunitinib is already approved by the FDA, EMEA and AEMPS for the treatment of patients with metastatic renal cell carcinomas and those with metastatic gastrointestinal stromal tumors (GIST) with progression or intolerance to imatinib. Suntinib has recently reported to be superior than placebo in terms of response rate (9.3% vs. 0%; p\<0.05), progression free survival (11.4 vs. 5,5 months; HR 0.41;p\<0.05), and overall survival (HR 0.40;p\<0.05) when administered in a phase 3 trial to patients with advanced pancreatic neuroendocrine tumors (NETs). Sunitinib is an expensive drug that drains the budget of health public system therefore it demands a rational drug use. Sunitinib is metabolized by CYP3A4, that belongs to the P450 cytochrome system in the liver. Most of the drug is eliminated in faeces and only 16% by urine. Sunitinib has no food-effect when taken with meals. Pharmacokinetics parameters did not differ between cancer patients and healthy volunteers. Houk et al. Showed that the area under the curve of plasmatic concentration of sunitinib and its active metabolite did correlate with clinical outcome. In other words, the higher plasma concentration area under the curve the highest rates of radiological response, progression free and overall survival rates. Ketoconazol is an antifungal drug that inhibits the CY3A4 inducing an elevation of peak plasma levels of other drugs administered simultaneously and that are metabolized by the same system. In the labeling sheet of sunitinib it is said that ketoconazol induced a 49% and 51% of increase of plasmatic sunitinib Cmax y AUC0-∞ when both drugs were administered together. This fact makes that the investigatorspropose that by administering both drugs simultaneously the investigators could reduce sunitinib dose by a lower metabolization with similar plasma concentration. The dose reduction would impact in drug cost. Here the investigators propose to determine the most optimal combination dose of sunitinib (25 mg or 37.5 mg) and ketoconazol (200mg o 400mg) by which the investigators could have plasmatic bioequivalent concentrations compared with single dose of sunitinib 50mg. Each volunteer will be assigned to a treatment arm (Arm A and Arm B). Volunteers included in Arm A will take: sunitinib 50 mg, sunitinib 37.5 mg + ketoconazole 200 mg and sunitinib 37.5 mg + 400 mg ketoconazole. Volunteers included in Arm B will take: sunitinib 50 mg, sunitinib 25 mg + ketoconazole 200 mg and sunitinib 25 mg + 400 mg ketoconazole

Conditions

Cancer

Keywords

Pharmacokinetic; Sunitinib; Ketoconazol; interaction, Phase I

Outcome Measures

Primary Outcomes (1)

• Sunitinib pharmacokinetic parameters (Maximum plasma concentration (Cmax) and Area under the plasma concentration curve (AUC0-72) obtained in the different treatment groups.

  On the fourth day of each period patient will be hospitalized in the clinical trial unit in order to obtain plasma concentrations previous to the administration of the corresponding dose and at the following times port-administration: 2h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 11h, 12h, 14h, 16h, 24h, 36h, 48h amd 72h. These measures will be calculated in order to describe the pharmacokinetic profile of each treatment arm.

  Up to 72 hours postdose for each period

Secondary Outcomes (4)

• Other Sunitinib pharmacokinetic parameters (first time to reach Cmax (tmax) and Area under the plasma concentration curve (AUC0-Inf) obtained in the different treatment groups.

  Up to 72 hours postdose for each period

• Coefficient of variation of AUC and Cmax

  9 months

• Change in QT interval

  On day 4 of each period

• Adverse events reported

  9 months

Study Arms (5)

Sunitinib 50mg

ACTIVE COMPARATOR

Sunitinib 50 mg administered as a single dose.

Drug: Sunitinib

Sunitinib 37.5mg + Ketoconazol 200mg

EXPERIMENTAL

The drugs will be administered as follows: * Sunitinib 37.5mg oral single dose. * Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)

Drug: Sunitiinb and Ketoconazol

Sunitinib 37.5 mg + Ketoconazol 400 mg

EXPERIMENTAL

The drugs will be administered as follows: * Sunitinib 37.5mg oral single dose. * Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)

Drug: Sunitinib and Ketoconazol

Sunitinib 25mg + Ketoconazol 200mg

EXPERIMENTAL

The drugs will be administered as follows: * Sunitinib 25mg oral single dose. * Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)

Drug: Sunitinib and Ketoconazol

Sunitinib 25mg + Ketoconazol 400mg

EXPERIMENTAL

The drugs will be administered as follows: * Sunitinib 25mg oral single dose. * Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)

Drug: Sunitinib and Ketoconazol

Interventions

Sunitinib DRUG

One capsule of sunitinib 50 mg orally. Single dose

Sunitinib 50mg

Sunitinib and Ketoconazol DRUG

Sunitinib capsule 37.5mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.

Sunitinib 37.5 mg + Ketoconazol 400 mg

Sunitiinb and Ketoconazol DRUG

Sunitinib capsule 37.5mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.

Sunitinib 37.5mg + Ketoconazol 200mg

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy individuals men who give their written consent to participate in the study, after having received information about the design, the project objectives, the risks and that at any moment they can refuse their cooperation.
• Age between 18 and 35 years.
• Subjects with a BMI that is between 19 and 28.
• Healthy subjects, without any organic or psychological pathology.
• Clinical history and physical examination within normal limits.
• Lack of clinically relevant abnormalities in blood test (hematology, biochemistry, virology) and urine test
• Vital signs and electrocardiographic recording in the normal range.

You may not qualify if:

• Subjects who have received prescription drug treatment in the last 15 days or any medication within 48 hours before receiving study medication.
• Known hypersensitivity to any drug
• Suspected of drug abuse

Sponsors & Collaborators

• Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal: lead

Study Sites (1)

Hospital Universitario Ramón y Cajal

Madrid, Madrid, 28034, Spain

Location

MeSH Terms

Conditions

Neoplasms

Interventions

Sunitinib; Ketoconazole

Intervention Hierarchy (Ancestors)

Pyrroles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Piperazines

Study Officials

• Enrique Grande Pulido

  Hospital Universitario Ramón y Cajal

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 23, 2011
• First Posted: March 8, 2012
• Study Start: April 1, 2011
• Primary Completion: July 1, 2011
• Study Completion: July 1, 2011
• Last Updated: March 8, 2012

Record last verified: 2012-03

Locations

ES (1)